Joint research to establish genetic testing for brain tumors
First written in FY2025-H1. 1 of 3 entries say "Restated". Latest entry: FY2026-H1.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「CPM has entered into a joint research agreement with Showa University Educational Corporation and Nonacus concerning the establishment of a genetic test for brain tumors.」
The joint research on a genetic test for brain tumors is now described as an agreement with Nonacus, following the transfer of operations changed from Advanced Genomics APAC to Nonacus. - FY2025RestatedAnnual report
「CPM has entered into a joint research agreement with Showa University Educational Corporation and Advanced Genomics APAC Co., Ltd. aimed at establishing a genetic test for brain tumors. The study seeks to comprehensively analyze, by next-generation sequencing for each patient, the genetic mutations arising in brain tumors and establish a genetic test for brain tumors whose results can be applied to the diagnosis and treatment of individual patients.」
CPM continues its joint research with Showa University and Advanced Genomics APAC Co., Ltd. on a genetic test for brain tumors. - FY2025-H1First statedAnnual report
「CPM has entered into a joint research agreement with Showa University Educational Corporation and Advanced Genomics APAC Co., Ltd. aimed at establishing a genetic test for brain tumors. The study seeks to comprehensively analyze, by next-generation sequencing for each patient, the genetic mutations arising in brain tumors and establish a genetic test for brain tumors whose results can be applied to the diagnosis and treatment of individual patients.」
CPM entered into a joint research agreement with Showa University and Advanced Genomics APAC Co., Ltd. and began a new testing study aimed at comprehensively analyzing genetic mutations in brain tumors for each patient and applying the results to diagnosis and treatment.